We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
I Agree
  • Dynacure Receives Orphan Drug Designation for DYN101 americanpharmaceuticalreview
    August 12, 2019
    Dynacure announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for DYN101, an investigational antisense medicine designed to modulate the expression of dynamin 2 (DNM2) for ...
  • Ionis-backed Dynacure bags €47M to start clinical trials fiercebiotech
    July 09, 2018
PharmaSources Customer Service